A Pharmacokinetic Interaction Study Between TMC435, Atorvastatin and Simvastatin in Healthy Participants
Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate effects of steady-state concentrations (constant
concentration of medication in the blood) of TMC435 on the single dose pharmacokinetics (what
the body does to the medication) of atorvastatin, the active metabolites ortho- and
parahydroxylated atorvastatin, simvastatin and the active metabolite simvastatin acid. Plasma
hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitory activity after a single
dose of atorvastatin or simvastatin, either alone or in combination with TMC435 will be also
evaluated.